Welcome to our dedicated page for Bioxytran news (Ticker: BIXT), a resource for investors and traders seeking the latest updates and insights on Bioxytran stock.
Bioxytran, Inc. (BIXT) is a clinical-stage biotechnology company whose news flow centers on antiviral drug development, oxygen transport therapies, and advances in stroke and Alzheimer’s research. Company press releases describe a pipeline that includes ProLectin-M, PHM23, and BXT-25, along with collaborations and scientific milestones that support these programs.
News updates frequently highlight clinical trial progress for ProLectin-M, an oral galectin antagonist antiviral being developed under an active IND with the FDA. Bioxytran has reported completion of randomized, double-blind, placebo-controlled trials and dose optimization studies, with endpoints focused on viral load reduction, symptom improvement, and safety. Releases also discuss regulatory interactions with agencies such as the FDA and India’s Central Drugs Standard Control Organization for future trial design.
Another recurring theme in Bioxytran’s news is its oxygen therapeutics platform. The company issues updates on BXT-25 and the Universal Oxygen Carrier project, including securing a GMP-quality source of camel hemoglobin through a joint venture with the Heme Foundation. Articles describe how this work ties into research on mitochondrial function, tissue oxygenation, and the use of the MDX Viewer as a real-time diagnostic tool in stroke and neurodegenerative disease studies.
Bioxytran’s news also covers scientific recognition and partnerships, such as the inclusion of its antiviral PHM23 in a University of Georgia grant submission for Bird Flu research, and publications by scientific advisors on oxygen homeostasis and brain models of ischemic stroke. In addition, the company has announced initiation of independent research coverage of its stock, reflecting interest from micro-cap and small-cap equity research specialists.
Investors and observers who follow BIXT news can expect updates on clinical trial milestones, regulatory submissions, scientific publications, collaborations with academic and nonprofit partners, and developments in its galectin-based antiviral and oxygen transport platforms.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
BIOXYTRAN, INC. (BIXT) announced successful animal testing results for its Acellular Oxygen Carrier BXT-25, designed to treat COVID-19 and other viral diseases. The treatment showed non-toxicity and full recovery in Swiss Albino mice, even after a significant blood loss. BXT-25 is significantly smaller than a blood cell, allowing it to reach hypoxic areas of the body, potentially revolutionizing treatment for conditions like strokes and neurodegenerative diseases. The company plans to conduct further toxicity studies and aims to submit an Investigational New Drug Application to the FDA for clinical trials on stroke patients. Initial non-clinical studies indicated no toxicity and effective oxygen delivery, bolstering the drug's therapeutic potential.
BIOXYTRAN, INC. (OTCQB: BIXT) is set to present new findings on its Long COVID research at the Emerging Growth Conference on April 5, 2023, from 10:50am to 11:20am EST. CCO Michael Sheikh will discuss a recent peer-reviewed journal article and engage with attendees. Investors are encouraged to preregister for the event to receive updates and have the opportunity to submit questions. Bioxytran is developing innovative antiviral treatments, focusing on unmet medical needs in virology. The conference serves as a platform for public companies to showcase advancements, attracting a broad audience of investors.
Bioxytran, Inc. (BIXT) announced promising results from a Phase 2 clinical trial for its Galectin antagonist, demonstrating a 100% viral load elimination in 34 patients with mild-to-moderate COVID-19 by day 7, compared to just 6% in the placebo group (p=.001). Most symptoms resolved within the same period. The trial showed an 82% responder rate by day 3 (p=.001) with no serious adverse events. These results support further studies, possibly a Phase 3 trial, highlighting the drug's potential in both treatment and prophylaxis against viral infections. Bioxytran aims to explore applications beyond COVID-19, tapping into Glycovirology.